2,5-双(三氟甲基)苯磺酰胺 | 951625-11-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,5-双(三氟甲基)苯磺酰胺
• 中文别名: 2,5-二(三氟甲基)苯磺酰胺,98；2,5-二(三氟甲基)苯磺酰胺
• 英文名称: 2,5-bis(trifluoromethyl)benzenesulfonamide
• CAS: 951625-11-9
• 化学式: C₈H₅F₆NO₂S
• 分子量: 293.19
• InChiKey: KQNPHVUXUGXXCV-UHFFFAOYSA-N

物化性质

• 熔点：
  145-148°C
• 沸点：
  324.1±52.0 °C(Predicted)
• 密度：
  1.581±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  9

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2935009090

反应信息

• 作为反应物：
  描述：

  2,5-双(三氟甲基)苯磺酰胺 、 indomethacin 在 N,N'-羰基二咪唑 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 为溶剂， 反应 22.0h， 以37%的产率得到N-[2,5-bis(trifluoromethyl)phenyl]sulfonyl-2-[1-(4-chlorobenzoyl)-5-methoxyindol-3-yl]acetamide
  参考文献：
  名称：

  Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer

  摘要：

  Castrate-resistant prostate cancer (CRPC) is a fatal, metastatic form of prostate cancer. CRPC is characterized by reactivation of the androgen axis due to changes in androgen receptor signaling and/or adaptive intratumoral androgen biosynthesis. AKR1C3 is upregulated in CRPC where it catalyzes the formation of potent androgens. This makes AKR1C3 a target for the treatment of CRPC. AKR1C3 inhibitors should not inhibit AKR1C1/AKR1C2, which inactivate 5 alpha-dihydrotestosterone. Indomethacin, used to inhibit cyclooxygenase, also inhibits AKR1C3 and displays selectivity over AKR1C1/AKR1C2. Parallel synthetic strategies were used to generate libraries of indomethacin analogues, which exhibit reduced cyclooxygenase inhibitory activity but retain AKR1C3 inhibitory potency and selectivity. The lead compounds inhibited AKR1C3 with nanomolar potency, displayed >100-fold selectivity over AKR1C1/AKR1C2, and blocked testosterone formation in LNCaP-AKR1C3 cells. The AKR1C3.NADP(+).2'-des-methyl-indomethacin crystal structure was determined, and it revealed a unique inhibitor binding mode. The compounds reported are promising agents for the development of therapeutics for CRPC.

  DOI：

  10.1021/jm3017656

文献信息

• Polymers containing grafted bis(sulfonyl)imide sodium or lithium salts, methods for production thereof and uses of same as electrolytes for batteries
  申请人：CDP INNOVATION

  公开号：US10141603B2

  公开（公告）日：2018-11-27

  The invention relates to novel polymers containing grafted sodium or lithium bis(sulfonyl)imides, to the methods for the production thereof, and to the uses of same as electrolytes in batteries.

  本发明涉及含有接枝钠或锂双(磺酰基)亚胺的新型聚合物、其生产方法以及用作电池电解质的用途。
• 一种高耐碱性和鲜艳度分散染料及其制备方法和应用
  申请人：南通大学

  公开号：CN115044224A

  公开（公告）日：2022-09-13

  本发明公开了一种高耐碱性和鲜艳度分散染料及其制备方法和应用，属于精细化工技术领域。本发明通过利用溴氨酸与含氟苯磺酰胺发生缩合反应，在染料结构中引入氟原子，利用氟原子与染料结构中的氢原子之间形成分子间/分子内氢键来提高相邻染料分子间的作用力，阻碍亲核试剂对易水解基团的进攻，从而达到提高染料耐碱稳定性的目的。同时通过在蒽醌母体结构中引入强吸电子性的含氟基团，进一步提高了染料的鲜艳度。本发明制备得到的分散染料解决了“现有的耐碱型分散染料可以在7≤pH≤14条件下应用，但碱剂只能为碳酸钠、碳酸氢钠、磷酸三钠、磷酸二氢钠或磷酸氢二钠等而不能为强碱NaOH”的问题，能达到在涤纶织物前处理和一浴染色法中的应用的要求。
• NOUVEAUX POLYMERES CONTENANT DES SELS DE LITHIUM OU DE SODIUM DE BIS(SULFONYL)IMIDES GREFFES, LEURS PROCEDES DE PREPARATION ET LEURS UTILISATIONS COMME ELECTROLYTES POUR BATTERIES
  申请人：CDP-Innovation

  公开号：EP3172264B1

  公开（公告）日：2021-06-16
• NOVEL POLYMERS CONTAINING GRAFTED BIS(SULFONYL)IMIDE SODIUM OR LITHIUM SALTS, METHODS FOR PRODUCTION THEREOF AND USES OF SAME AS ELECTROLYTES FOR BATTERIES
  申请人：CDP INNOVATION

  公开号：US20170179526A1

  公开（公告）日：2017-06-22

  The invention relates to novel polymers containing grafted sodium or lithium bis(sulfonyl)imides, to the methods for the production thereof, and to the uses of same as electrolytes in batteries.
• Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer
  作者：Andy J. Liedtke、Adegoke O. Adeniji、Mo Chen、Michael C. Byrns、Yi Jin、David W. Christianson、Lawrence J. Marnett、Trevor M. Penning

  DOI：10.1021/jm3017656

  日期：2013.3.28

  Castrate-resistant prostate cancer (CRPC) is a fatal, metastatic form of prostate cancer. CRPC is characterized by reactivation of the androgen axis due to changes in androgen receptor signaling and/or adaptive intratumoral androgen biosynthesis. AKR1C3 is upregulated in CRPC where it catalyzes the formation of potent androgens. This makes AKR1C3 a target for the treatment of CRPC. AKR1C3 inhibitors should not inhibit AKR1C1/AKR1C2, which inactivate 5 alpha-dihydrotestosterone. Indomethacin, used to inhibit cyclooxygenase, also inhibits AKR1C3 and displays selectivity over AKR1C1/AKR1C2. Parallel synthetic strategies were used to generate libraries of indomethacin analogues, which exhibit reduced cyclooxygenase inhibitory activity but retain AKR1C3 inhibitory potency and selectivity. The lead compounds inhibited AKR1C3 with nanomolar potency, displayed >100-fold selectivity over AKR1C1/AKR1C2, and blocked testosterone formation in LNCaP-AKR1C3 cells. The AKR1C3.NADP(+).2'-des-methyl-indomethacin crystal structure was determined, and it revealed a unique inhibitor binding mode. The compounds reported are promising agents for the development of therapeutics for CRPC.